* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:41:26 ON 13 NOV 2000

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:41:35 ON 13 NOV 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 12 NOV 2000 HIGHEST RN 302542-21-8
DICTIONARY FILE UPDATES: 12 NOV 2000 HIGHEST RN 302542-21-8

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> s wvq/sqsp

L1 4364 WVQ/SQSP

=> s kqk/sqsp

L2 21348 KQK/SQSP

=> s kqk/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> s wvq/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> help stn

For additional assistance with system features and files, you may contact the STN Help Desk at the nearest STN Service Center.

In USA and Canada:

STN International
Chemical Abstracts Service
PO Box 02228
Columbus, OH 43202 USA

Phone: 800-848-6533
614-447-3698
800-848-6538 (in Ohio and Canada)

Hours: 8:00 am to 8:00 pm
US Eastern Time
Telex: 6842086 CHMAB
Telefax: 614-447-3798
STNmail: HLPDESKC
E-mail: help@cas.org

In Europe:

STN International
FIZ Karlsruhe
Postfach 2465
D-76012 Karlsruhe
Germany

Phone: (+49)-7247/808-555
Hours: 7:30 am to 6:00 pm
Central European Time
Telex: 17724710+
Telefax: (+49) 7247/808-259
STNmail: HLPDESKK
E-mail: hlpdeskk@fiz-karlsruhe.de

In Japan:

STN International
c/o Japan Science and Technology
Corporation (JST)
5-3 Yonbancho, Chiyoda-ku
Tokyo 102-0081, Japan

Phone: (+81) 3-5214-8414
Toll free: 0120-521022
(in Japan Only)
Hours: 9:00 am to 5:00 pm
Japan Time
Telefax: (+81) 3-5214-8410
STNmail: HLPDESKT
E-mail: helpdesk@mr.jst.go.jp
http:www://jst.go.jp/

You may use the SEND command in the STNMAIL File to contact any Service Center. If you want a particular Center to contact you, be sure to include that information in your message.

```
=> s sql<=30

L3      708565 SQL<=30

=> s kqk/sqsp and sql<=30

           538 KQK/SQSP
        708565 SQL<=30
L4         538 KQK/SQSP AND SQL<=30

=> s wvq/sqsp and sql<=30

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s wvq/sqsp and sql<=20

COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> file caplus

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               84.60      84.81

FILE 'CAPLUS' ENTERED AT 14:50:19 ON 13 NOV 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1967 - 13 Nov 2000 VOL 133 ISS 21
FILE LAST UPDATED: 12 Nov 2000 (20001112/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

```
=> d his


     (FILE 'HOME' ENTERED AT 14:41:26 ON 13 NOV 2000)

     FILE 'REGISTRY' ENTERED AT 14:41:35 ON 13 NOV 2000
L1          4364 S WVQ/SQSP
L2         21348 S KQK/SQSP
L3        708565 S SQL<=30
L4           538 S KQK/SQSP AND SQL<=30

     FILE 'CAPLUS' ENTERED AT 14:50:19 ON 13 NOV 2000

=> s l4

L5          279 L4

=> dup rem l5

PROCESSING COMPLETED FOR L5
L6          279 DUP REM L5 (0 DUPLICATES REMOVED)

=> l6 and chemokine

L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l6 and chemokine

L7          279 S L6
           5648 CHEMOKINE
           4785 CHEMOKINES
           6703 CHEMOKINE
                  (CHEMOKINE OR CHEMOKINES)
L8            6 L7 AND CHEMOKINE

=> d l8 total ibib kwic


L8   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2000 ACS
ACCESSION NUMBER:         2000:493573  CAPLUS
DOCUMENT NUMBER:          133:134180
```

TITLE: Compounds and methods to inhibit or augment an inflammatory response

INVENTOR(S): Grainger, David J.; Tatalick, Lauren Marie

PATENT ASSIGNEE(S): Neorx Corporation, USA

SOURCE: PCT Int. Appl., 387 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042071	A2	20000720	WO 2000-US821	20000112

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1999-229071	19990112
US 1999-271192	19990317
US 1999-452406	19991201

OTHER SOURCE(S): MARPAT 133:134180

AB Isolated and purified **chemokine** peptides, variants, and derivs. thereof, as well as **chemokine** peptide analogs, are provided. The **chemokine** peptide 3 derivs. are useful for preventing or treating diseases assocd. with recruitment of hematopoietic cells, and histamine release from basophils or mast cells; stroke; vascular disease (e.g. coronary artery disease, myocardial infarction, unstable angina pectoris, atherosclerosis or vasculitis); low bone mineral d.; autoimmune diseases; tumor; psoriasis; wound healing; asthma; organ transplant rejection; rheumatoid arthritis; allergy; inhibition of antigen-induced recall response; lentivirus infection or HIV infection; and parasitic or malaria infection.

ST **chemokine** peptide 3 agonist antagonist inflammation

IT **Chemokines**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(3 peptide; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Blood-group substances
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Duffy; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SDF-1 (stromal-derived factor-1); **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Heart, disease
(angina pectoris, unstable; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Organic compounds, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(biol.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Mineral elements, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,

unclassified); BIOL (Biological study)
(bone, low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Allergy
Antitumor agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Basophil
Blood vessel, disease
Erythrocyte
Immunostimulation
Immunotherapy
Indicators
Inflammation
Mast cell
Protein sequences
Psoriasis
Rheumatoid arthritis
Transplant rejection
Vaccines
Vertebrate (Vertebrata)
Wound healing
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Immunoglobulins
Interleukin 4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Tumor necrosis factors
RL: BOC (Biological occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokine** receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Antigens
Interleukin 8
Leukotrienes
Macrophage inflammatory protein 1.alpha.
Macrophage inflammatory protein 1.beta.
Monocyte chemoattractant protein-1
Prostaglandins
Thromboxanes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Neutrophil-activating peptide-2
Peptides, biological studies
Proteins, general, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Disease, animal
(**chemokine** activity-assocd.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Carbohydrates, biological studies
Monosaccharides
Polysaccharides, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** peptide conjugate; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Artery, disease
(coronary; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Immunity
(immunol. memory, recall; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Heart, disease
(infarction; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Human immunodeficiency virus
Lentivirus
Malaria
Parasite
(infection; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Bone, disease
(low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Bone
(minerals, low d.; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocyte chemoattractant protein 3; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocyte chemoattractant protein-2; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Hematopoietic precursor cell
(recruitment; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Brain, disease
(stroke; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT Blood vessel, disease
(vasculitis; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 51-45-6, Histamine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 506-32-1, Arachidonic acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 3062-07-5 4685-12-5 13184-14-0 24613-12-5 35193-18-1 36301-96-9
38579-27-0 51790-17-1 54532-75-1 54925-87-0 54944-27-3
56395-09-6 57625-86-2 57625-90-8 66138-71-4 85807-09-6
106325-99-9 106326-00-5 106326-01-6 106326-02-7 106326-71-0
114148-97-9 114991-28-5 115416-08-5 130036-94-1 146436-61-5
147841-68-7 151367-92-9 155575-02-3 175176-05-3 180511-27-7
193413-93-3 **221172-52-7** **221172-53-8** 221172-54-9
221172-55-0 **221172-56-1** 221172-57-2
221172-58-3 **221172-59-4** **221172-61-8**
221172-62-9 221172-63-0 221172-64-1 221172-65-2
221172-67-4 221172-69-6 221172-71-0 **221172-73-2**
221172-74-3 **221172-75-4** 221172-76-5 221172-78-7
221172-80-1 **221172-81-2** **221172-82-3**
221172-83-4 221172-84-5 221172-85-6 221172-86-7
221172-87-8 221172-89-0 221172-91-4 221172-95-8 221172-96-9

221173-06-4 221173-07-5 243662-32-0 248585-56-0 284495-25-6
284495-26-7 284495-27-8 **284495-28-9 284495-29-0**
284495-30-3D, biotinylated 284495-34-7 284495-36-9
284495-37-0 284495-38-1 284495-39-2 284495-40-5
284495-41-6 284495-42-7 **284495-43-8**
284495-45-0 284495-46-1 284495-47-2 284495-49-4
284495-50-7 284495-51-8 284495-52-9 284495-53-0 284495-54-1
284495-55-2 284495-56-3 284495-57-4
284495-58-5 284495-59-6D, biotinylated 284495-60-9
284495-61-0 284495-62-1 284495-62-1D, biotinylated 284495-63-2
284495-64-3 284495-65-4D, biotinylated 284495-66-5 284495-68-7
284495-69-8 284495-70-1 284495-71-2 284677-98-1
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 24196-29-0P 284495-33-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 9004-10-8, Insulin, biological studies 12629-01-5, Human growth hormone
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 284495-31-4P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 56-85-9, L-Glutamine, reactions 82-58-6, Lysergic acid 38460-95-6, 10-Undecenoyl chloride 128625-52-5, PyBOP 284495-32-5
RL: RCT (Reactant)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 54350-44-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(**chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 102619-57-8, Lymphokine MIP 1.alpha. (human clone pLD78 macrophage inflammatory precursor reduced) 111366-43-9, Interleukin 8 (human clone 3-10C precursor reduced) 113755-98-9, Melanoma growth stimulatory activity (human isoform .alpha. precursor reduced) 118366-81-7, Lymphokine MCP 1 (mouse clone .lambda.JE-1 precursor protein moiety reduced) 122318-61-0, Lymphokine MIP 1.beta. (human clone pAc-Act2 macrophage inflammatory precursor reduced) 124147-40-6, Lymphokine MCP 1
(human precursor protein moiety reduced) 125267-37-0 128002-31-3, Protein I 309 (human clone MB5-2 precursor reduced) 130938-43-1, Cytokine CRG 2 (mouse clone 1.1-1 precursor reduced) 131201-04-2, Lymphokine MIP 2.alpha. (human clone hMIP-2-5a macrophage inflammatory precursor reduced) 147855-88-7, Monokine (human clone H-1-3 gene mig interferon .gamma.-inducible precursor reduced) 158132-79-7 161348-23-8 163548-48-9 163548-49-0, Lymphokine (human gene RANTES fragment) 167616-16-2 167616-19-5 168257-03-2 175138-24-6, Eotaxin
(human clone 25 precursor) 177404-40-9, **Chemokine** .beta.-10

(human precursor) 286026-09-3 286370-36-3
RL: PRP (Properties)
(unclaimed protein sequence; compds. and methods to inhibit or augment an inflammatory response)

IT 284495-35-8 284495-48-3 284495-67-6
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unclaimed sequence; **chemokine** 3 peptide analogs for treating inflammatory diseases)

IT 70364-88-4 134365-65-4 162290-78-0 162559-42-4 167871-05-8
221172-72-1 221172-77-6 221172-79-8 221172-98-1
221172-99-2 221173-00-8 221173-01-9 221173-02-0 221173-03-1
221173-04-2 286000-61-1 286000-62-2 286000-63-3 286000-64-4
286000-65-5 286000-66-6 286000-67-7 286000-68-8 286000-69-9
286000-71-3 286000-72-4 286000-74-6 286000-76-8 286000-78-0
286000-80-4 286000-82-6 286000-84-8 286000-86-0 286000-88-2
286000-90-6 286000-92-8 286000-94-0 286000-95-1 **286001-03-4**
286001-04-5 286001-05-6
RL: PRP (Properties)
(unclaimed sequence; compds. and methods to inhibit or augment an inflammatory response)

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 2000:47964 CAPLUS
DOCUMENT NUMBER: 132:273746
TITLE: Quantitative Analysis of a Synthetic Peptide, NR58-3.14.3, in Serum by LC-MS with Inclusion of a Diastereomer as Internal Standard
AUTHOR(S): Wilbert, Sibylle M.; Engrissei, Gina; Yau, Eric K.; Grainger, David J.; Tatalick, Lauren; Axworthy, Don B.
CORPORATE SOURCE: NeoRx Corporation, Seattle, WA, 98119-4007, USA
SOURCE: Anal. Biochem. (2000), 278(1), 14-21
CODEN: ANBCA2; ISSN: 0003-2697
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17
REFERENCE(S): (1) Allievi, C; Rapid Commun Mass Spectrom 1998, V12, P33 CAPLUS
(2) Carrascal, M; J Pharm Bio Anal 1998, V17, P1129 CAPLUS
(3) Clarke, N; FEBS Lett 1998, V430, P419 CAPLUS
(6) Jameson, B; Nature 1994, V368, P744 CAPLUS
(7) Kikuchi, K; J Mass Spectrom 1999, V34, P93 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

ST peptide synthetic **chemokine** pharmacokinetics blood LC MS internal std

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

IT **263771-13-7P**
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(synthetic, NR58-3.14.3; quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

IT **263771-14-8P**
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(synthetic, NR58-3.14.5; quant. anal. of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal std.)

L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:819270 CAPLUS
DOCUMENT NUMBER: 132:69369
TITLE: Compositions and methods for delivery of agents for altering neuronal growth, regeneration, and survival
INVENTOR(S): Baird, Andrew; Berry, Martin; Logan, Ann; Gonzalez, Ana Maria
PATENT ASSIGNEE(S): Selective Genetics, Inc., USA
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966959	A2	19991229	WO 1999-US12126	19990601
WO 9966959	A3	20000504		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9962380	A1	20000110	AU 1999-62380	19990601
PRIORITY APPLN. INFO.:			US 1998-88419	19980601
			US 1998-178286	19981023
			WO 1999-US12126	19990601

IT **Chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CXC family; gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

IT **Chemokines**
RL: BAC (Biological activity or effector, except adverse); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ENA-78; gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

IT 113516-56-6 132328-28-0 152551-92-3 202601-31-8 205385-47-3
244050-78-0 253328-14-2 253328-15-3 253328-16-4 253328-17-5
253328-19-7 253328-21-1 **253328-22-2** 253328-23-3
253328-24-4 253328-25-5 253328-26-6 253328-27-7
253328-28-8 253328-29-9 253328-30-2
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(gene therapy and delivery of agents for altering neuronal growth, regeneration, and survival)

L8 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:477233 CAPLUS
DOCUMENT NUMBER: 131:270612
TITLE: Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides
AUTHOR(S): Vella, John P.; Magee, Colm; Vos, Lydia; Womer, Karl; Rennke, Helmut; Carpenter, Charles B.; Hancock, Wayne;

Sayegh, Mohamed H.
CORPORATE SOURCE: Laboratory of Immunogenetics and Transplantation, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
SOURCE: Transplantation (1999), 67(12), 1523-1532
CODEN: TRPLAU; ISSN: 0041-1337
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 43
REFERENCE(S):
(2) Auchincloss, H; Proc Natl Acad Sci USA 1993, V90(8), P3373 CAPLUS
(3) Benham, A; Transplantation 1994, V58(11), P1236 CAPLUS
(5) Benichou, G; Immunol Today 1997, V18, P67 CAPLUS
(6) Benichou, G; J Exp Med 1992, V175, P305 CAPLUS
(8) Chandraker, A; J Clin Invest 1998, V101(11), P2309 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB To investigate the role and mechanisms of indirect allorecognition in allograft rejection, we studied whether priming T cells with donor-derived MHC allopeptides could accelerate rejection in a vascularized allograft model. Lewis recipients of fully mismatched Wistar Furth cardiac allografts were immunized before transplantation with donor MHC allopeptides. Animals immunized with immunogenic class II MHC allopeptides rejected their grafts in a significantly accelerated fashion compared with controls. Addnl. studies demonstrated that a single immunodominant RT1.D (HLA-DR like) allopeptide was responsible for accelerating the rejection process. Histol. anal. of rejected allografts revealed marked vascular rejection in the accelerated, although not the control, group as well as severe cellular rejection. Peak prodn. of IgM and IgG donor-specific alloantibodies was detected by flow cytometry 1 wk earlier in the sera of the accelerated group compared with the control group. Immunohistol. anal. of grafts from the accelerated compared with the control group showed increased endothelial deposition of IgG2b, C3, and fibrin, and up-regulation of class II MHC mol. expression. Increased intragraft expression of interferon-.gamma. and the interferon-.gamma.-induced **chemokines**, inducible protein-10 and Mig, and infiltration by activated mononuclear cells expressing CXCR3, the receptor for inducible protein-10 and Mig, was also seen. These novel data provide evidence of a definitive link between indirect allorecognition of donor-derived MHC class II peptides and the cellular and humoral mechanisms of vascularized allograft rejection.

IT 152684-06-5P 152684-08-7P 152684-11-2P 187099-83-8P 187099-84-9P 245663-46-1P 245663-47-2P **245663-48-3P**
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides in rat)

L8 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:443132 CAPLUS
DOCUMENT NUMBER: 131:208594
TITLE: Identification of oligopeptide sequences which inhibit migration induced by a wide range of **chemokines**
AUTHOR(S): Reckless, Jill; Grainger, David J.
CORPORATE SOURCE: Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK
SOURCE: Biochem. J. (1999), 340(3), 803-811

CODEN: BIJOAK; ISSN: 0264-6021
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 32
REFERENCE(S):
(1) Ahuja, S; Immunol Today 1994, V15, P281 CAPLUS
(2) Bleul, C; Nature (London) 1996, V382, P829 CAPLUS
(3) Brown, Z; J Leukocyte Biol 1996, V59, P75 CAPLUS
(4) Cocchi, F; Science 1995, V270, P1811 CAPLUS
(5) Conti, P; Blood 1997, V89, P4120 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Identification of oligopeptide sequences which inhibit migration induced by a wide range of **chemokines**

AB The authors have identified an amino acid sequence, termed peptide 3, corresponding to amino acids 51-62 of the mature human monocyte chemoattractant protein-1 (MCP-1), which inhibits human mononuclear-cell and THP-1-cell migration induced by a wide range of **chemokines**. For example, peptide 3 inhibited MCP-1-induced THP-1 migration in a transwell assay with an ED50 of approx. 8.mu.M. Peptide 3 binds directly to THP-1 cells with an assocn. const. of approx. 10.mu.M, and is therefore likely to be a direct receptor antagonist for CC and CXC **chemokine** receptors. By performing a structure-function anal. of this peptide, the authors have identified a sequence variant that shows an approx. 3-4-fold greater potency as an inhibitor of **chemokine**-induced migration [Leu4Ile11 peptide 3 (1-12)]. Furthermore, unlike peptide 3, which binds to the Duffy antigen receptor for **chemokines** on human erythrocytes with a similar affinity to the specific **chemokine** receptors on THP-1 cells, the Leu4Ile11 peptide 3 (1-12) sequence variant shows at least 20-fold greater selectivity for the specific receptors. Derivs. of Leu4Ile11 peptide 3 (1-12) are therefore the best candidates among the mols. the authors have investigated for use as a **chemokine** inhibitor in vivo.

ST oligopeptide sequence mononuclear cell migration **chemokine**

IT **Chemokines**
(C-X-C, stromal cell-derived factor-1.alpha.; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Mononuclear cell (leukocyte)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Interleukin 8
Macrophage inflammatory protein 1.alpha.
Monocyte chemoattractant protein-1
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT **Chemokine** receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Structure-activity relationship
(leukocyte migration-inhibiting; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

IT Cell migration
(leukocyte; identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine**

receptors)

IT **221172-52-7P 221172-53-8P** 221172-54-9P
221172-55-0P 221172-56-1P 221172-57-2P
221172-58-3P 221172-59-4P 221172-87-8P 243662-32-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(identification of oligopeptide sequences which inhibit migration of mononuclear cells induced by a wide range of **chemokines** in relation to mediation by **chemokine** receptors)

L8 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:194178 CAPLUS
DOCUMENT NUMBER: 130:236476
TITLE: **Chemokine**-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses
INVENTOR(S): Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.
PATENT ASSIGNEE(S): Neorx Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912968	A2	19990318	WO 1998-US19052	19980911
WO 9912968	A3	19990729		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9893153	A1	19990329	AU 1998-93153	19980911
EP 1012187	A2	20000628	EP 1998-946057	19980911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1997-927939	19970911
			WO 1998-US19052	19980911

TI **Chemokine**-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses

AB The authors disclose the identification and characterization of **chemokine**-derived peptides, substituted variants and isosteres, and peptidic mimics that exhibit agonistic and antagonistic activity for **chemokine** receptors. In one example, a peptide derived from a conserved region of human monocyte chemoattractant protein-1 (MCP-1) was shown to inhibit the migration of the THP-1 cell line in response to MIP-1.alpha., MCP-1, SDF-1.alpha., and IL-8. Thus, inhibition was both specific and general. In addn., cyclic and reverse D-enantiomeric analogs of the peptide exhibited improved antagonistic activity. In a second example, a peptide derived from a non-conserved portion of MCP-1 was shown to inhibit CXCR4-mediated infection of Jurkat cells by HIV.

ST **chemokine** peptide antiinflammatory

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CK.beta.8; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Blood groups

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(Duffy; **chemokine**-derived peptides, peptide variants, derivs. and analogs as antagonists of ligands for)

IT C-X-C **chemokines**
(ENA78; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(GRO.gamma.; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HCC-1; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I309; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LARC; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(SDF-1; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TARC; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-X-C **chemokines**
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Eotaxin
Interferon inducible protein IP-10
Interleukin 8
MGSA **chemokine**
Macrophage inflammatory protein 1.alpha.
Macrophage inflammatory protein 1.beta.
Monocyte chemoattractant protein-1
Neutrophil-activating peptide-2
RANTES (**chemokine**)
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Peptidomimetics
(as **chemokine** agonists and antagonists)

IT Pseudopeptides
Tripeptides
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as **chemokine** agonists and antagonists)

IT Adjuvants (immunological)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT Anti-AIDS drugs
Anti-ischemic agents
Antianginal agents
Antiasthmatics
Antiatherosclerotics
Antihypertensives
Antimalarials
Antiosteoporotic agents
Antirheumatic drugs

Antitumor agents
Antiviral agents
Contraceptives
Parasiticides
Tuberculostatics
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT **Chemokine** receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as antagonists of)

IT Allergy inhibitors
T cell infection
Transplant rejection
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of)

IT Lentivirus
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of infection by)

IT Tumor necrosis factor .alpha.
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of inflammatory response to)

IT Leukotrienes
Prostaglandins
Thromboxanes
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of metab. of)

IT Wound healing (animal)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs for)

IT Leukocyte infiltration
Mast cell degranulation
(**chemokine**-derived peptides, peptide variants, derivs. and analogs for inhibition of)

IT Vaccines
(**chemokine**-derived peptides, peptide variants, derivs. and analogs in)

IT Basophil
(degranulation; **chemokine**-derived peptides, peptide variants, derivs. and analogs for inhibition of)

IT Cytokines
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, **chemokine** inhibitors; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT Autoimmune diseases
Endotoxemia
Psoriasis
Vasculitis
(inhibitors; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT C-C **chemokines**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(monocyte chemoattractant protein 3; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT C-C **chemokines**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(monocyte chemoattractant protein-2; agonistic and antagonistic activity of peptides, peptide variants, derivs. and analogs of)

IT Peptides, biological studies
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retro-inverso; as **chemokine** agonists and antagonists)

IT Myocardial infarction

(therapeutic agents; **chemokine**-derived peptides, peptide variants, derivs. and analogs as)

IT **221172-52-7**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 13184-14-0 54532-75-1 57625-86-2 106326-00-5 **221172-53-8**
221172-54-9 **221172-55-0** **221172-56-1** 221172-57-2
221172-58-3 **221172-59-4** **221172-60-7**
221172-61-8 **221172-62-9** 221172-63-0 221172-64-1
221172-65-2 221172-66-3 221172-67-4 221172-68-5 221172-69-6
221172-70-9 221172-71-0 **221172-72-1** **221172-73-2**
221172-74-3 **221172-75-4** 221172-76-5 221172-77-6
221172-78-7 221172-79-8 221172-80-1 **221172-81-2**
221172-82-3 **221172-83-4** 221172-84-5 221172-85-6
221172-86-7 221172-87-8 221172-88-9 221172-89-0 221172-90-3
221172-91-4 221172-92-5 221172-95-8 221172-96-9 221172-97-0
221172-98-1 221172-99-2 221173-00-8 221173-01-9 221173-02-0
221173-03-1 221173-04-2 221173-05-3 221173-06-4 221173-07-5
221173-47-3 221173-48-4
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 108-94-1D, Cyclohexanone, derivs.
RL: PRP (Properties)
(agonist and antagonist activity of **chemokine**-derived peptides, peptide variants, derivs. and analogs)

IT 221197-23-5P, Trypilamine
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(as **chemokine** antagonist)

IT 506-32-1, Arachidonic acid
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**chemokine**-derived peptides, peptide variants, derivs. and analogs as inhibitors of metab. of)

=> s l7 and inhibitor

329026 INHIBITOR
351160 INHIBITORS
536944 INHIBITOR
(INHIBITOR OR INHIBITORS)
L9 26 L7 AND INHIBITOR

=> d l9 total

L9 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:628260 CAPLUS
DN 133:221613
TI Site-specific mutated allergens for decreased clinical reaction to allergy
IN Bannon, Gary A.; Burks, A. Wesley, Jr.; Sampson, Hugh A.; Sosin, Howard B.; King, Nina E.; Maleki, Soheila J.; Connaughton, Cathie; Kopper, Randall A.; Rabjohn, Patrick A.; Shin, David S.; Compadre, Cesar M.
PA The Board of Trustees of the University of Arkansas, USA; Mount Sinai School of Medicine of New York University
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052154	A2	20000908	WO 2000-US5487	20000302

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-122566 19990302
US 1999-122960 19990303
US 1999-267719 19990311
US 2000-494096 20000128

L9 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:609013 CAPLUS
DN 133:205085
TI High throughput assay for protein modification
IN Colyer, John; Craig, Roger Kingdon; Maschio, Antonio; Mezna, Mokdad
PA Fluorescience Limited, UK
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050902	A2	20000831	WO 2000-GB669	20000225

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI GB 1999-4398 19990225

L9 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:351544 CAPLUS
DN 133:9081
TI Modified and truncated penetratin derivatives as membrane translocation carriers for drug transport
IN Fischer, M. Peter; Zhelev, Nikolai
PA Cyclacel Limited, UK
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000029427	A2	20000525	WO 1999-GB3750	19991111
	WO 2000029427	A3	20001005		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 2346616 A1 20000816 GB 1999-26719 19991111

PRAI GB 1998-25000 19981113
GB 1998-25001 19981113
GB 1999-2522 19990204
GB 1999-2525 19990204
GB 1999-14578 19990622

L9 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:291095 CAPLUS
DN 132:329919
TI Modified peptides containing an antibody Fc domain as therapeutic agents
IN Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PA Amgen Inc., USA
SO PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000024782	A2	20000504	WO 1999-US25044	19991025

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-105371 19981023
US 1999-428082 19991022

L9 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:171099 CAPLUS
DN 132:212676
TI Compositions containing nucleic acids and ligands for therapeutic treatment
IN Baird, J. Andrew; Chandler, Lois Ann; Sosnowski, Barbara A.
PA Selective Genetics, Inc., USA
SO U.S., 131 pp., Cont.-in-part of U.S. Ser. No. 441,979, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6037329	A	20000314	US 1996-718904	19960924
CA 2221269	AA	19961121	CA 1996-2221269	19960516
WO 9636362	A1	19961121	WO 1996-US7164	19960516

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML

AU 9658628	A1	19961129	AU 1996-58628	19960516
AU 710309	B2	19990916		
EP 833665	A1	19980408	EP 1996-920274	19960516

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 11505805	T2	19990525	JP 1996-535090	19960516

PRAI US 1994-213446 19940315
US 1994-213447 19940315
US 1994-297961 19940829

US 1994-305771 19940913
US 1995-441979 19950516
WO 1996-US7164 19960516
RE.CNT 48
RE
(2) Anon; WO 9012597 1990 CAPLUS
(3) Anon; WO 9118012 1991 CAPLUS
(4) Anon; WO 9204918 1992 CAPLUS
(5) Anon; WO 9317669 1993 CAPLUS
(6) Anon; WO 9325688 1993 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 2000:98600 CAPLUS
DN 132:161230
TI **Inhibitors** of HIV membrane fusion, and identification method
IN Eckert, Debra M.; Chan, David C.; Malashkevich, Vladimir; Carr, Peter A.; Kim, Peter S.
PA Whitehead Institute for Biomedical Research, USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006599	A1	20000210	WO 1999-US17351	19990730

W: CA, JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1998-94676 19980730
US 1998-100265 19980914
US 1998-101058 19980918
US 1999-132295 19990503
OS MARPAT 132:161230
RE.CNT 5
RE
(1) Chan, D; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1998, V95, P1513
(2) Eckert, D; CELL 1999, V99, P103 CAPLUS
(3) Judice, J; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1997, V94, P13426 CAPLUS
(4) Univ Duke; WO 9402505 A 1994
(5) Weissenhorn, W; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1997, V94, P6065 CAPLUS

L9 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:819270 CAPLUS
DN 132:69369
TI Compositions and methods for delivery of agents for altering neuronal growth, regeneration, and survival
IN Baird, Andrew; Berry, Martin; Logan, Ann; Gonzalez, Ana Maria
PA Selective Genetics, Inc., USA
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966959	A2	19991229	WO 1999-US12126	19990601
	WO 9966959	A3	20000504		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 9962380	A1	20000110	AU 1999-62380	19990601
PRAI	US 1998-88419	19980601			
	US 1998-178286	19981023			
	WO 1999-US12126	19990601			

L9 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:736736 CAPLUS
DN 131:346503
TI Peptides derived from frameshift-mutated genes which elicit T cell immunity and their use as cancer vaccines
IN Gaudernack, Gustav; Eriksen, Jon Amund; Moller, Mona; Gjertsen, Marianne Klemp; Saeterdal, Ingvil
PA Norsk Hydro Asa, Norway
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958552	A2	19991118	WO 1999-NO143	19990503
	WO 9958552	A3	20000302		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	NO 9802097	A	19991109	NO 1998-2097	19980508
	AU 9954516	A1	19991129	AU 1999-54516	19990503
PRAI	NO 1998-2097	19980508			
	WO 1999-NO143	19990503			

L9 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:673065 CAPLUS
DN 131:318568
TI Chimeric protease comprising human subtilisin fragment(s), and uses thereof for pharmaceutical applications and for reducing the allergenicity of non-human proteases
IN Estell, David
PA Genencor International, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953078	A2	19991021	WO 1999-US8177	19990415
	WO 9953078	A3	20000420		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9936432 A1 19991101 AU 1999-36432 19990415

PRAI US 1998-60854 19980415

WO 1999-US8177 19990415

L9 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1999:502773 CAPLUS

DN 131:139482

TI Methods to identify immunomodulators using cognate interaction of PKC-.theta.

IN Vasquez, Nicki J.; Ron, Dorit; Voronova, Anna F.; Napolitano, Eugene W.

PA Terrapin Technologies, Inc., USA

SO U.S., 67 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5935803	A	19990810	US 1996-665647	19960618
	US 5519003	A	19960521	US 1994-190802	19940201
	US 5783405	A	19980721	US 1995-541964	19951010
	US 5776716	A	19980707	US 1996-594447	19960131
	CA 2233313	AA	19970417	CA 1996-2233313	19961010
	WO 9714038	A1	19970417	WO 1996-US16195	19961010
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9673986	A1	19970430	AU 1996-73986	19961010
	EP 882228	A1	19981209	EP 1996-936307	19961010
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000500964	T2	20000202	JP 1997-515169	19961010
	US 6054286	A	20000425	US 1999-232130	19990115

PRAI US 1994-190802 19940201
US 1995-473089 19950607
US 1995-477346 19950607
US 1995-541964 19951010
US 1996-594447 19960131
US 1995-487072 19950607
US 1996-665647 19960618
WO 1996-US16195 19961010

RE.CNT 24

RE

(1) Anon; WO 9521252 1995 CAPLUS
(3) Dynlacht, B; Nature 1993, V363, P176 CAPLUS
(4) Fields; US 5283173 1994 CAPLUS
(5) Fong, H; Proc Natl Acad Sci USA 1986, V83, P2162 CAPLUS
(6) Guillemot, F; Proc Natl Acad Sci USA 1989, V86, P4594 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2000 ACS

AN 1999:443132 CAPLUS

DN 131:208594

TI Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines

AU Reckless, Jill; Grainger, David J.

CS Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, CB2 2QQ, UK

SO Biochem. J. (1999), 340(3), 803-811
CODEN: BIJOAK; ISSN: 0264-6021

PB Portland Press Ltd.

DT Journal

LA English

RE.CNT 32

RE
(1) Ahuja, S; Immunol Today 1994, V15, P281 CAPLUS
(2) Bleul, C; Nature (London) 1996, V382, P829 CAPLUS
(3) Brown, Z; J Leukocyte Biol 1996, V59, P75 CAPLUS
(4) Cocchi, F; Science 1995, V270, P1811 CAPLUS
(5) Conti, P; Blood 1997, V89, P4120 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:194178 CAPLUS
DN 130:236476
TI Chemokine-derived peptides, peptide variants, derivatives and analogs for modulation of inflammatory responses
IN Grainger, David J.; Tatalick, Lauren Marie; Kanaly, Suzanne T.
PA Neorx Corporation, USA
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9912968	A2	19990318	WO 1998-US19052	19980911
	WO 9912968	A3	19990729		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9893153	A1	19990329	AU 1998-93153	19980911
	EP 1012187	A2	20000628	EP 1998-946057	19980911
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1997-927939		19970911		
	WO 1998-US19052		19980911		

L9 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:147365 CAPLUS
DN 130:205126
TI Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
IN Miller, Jonathan L.; Lyle, Vicki A.
PA The Research Foundation of State University of New York, USA
SO U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 406,330.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5877155	A	19990302	US 1995-556597	19951113
	US 5817748	A	19981006	US 1995-406330	19950317
	WO 9718236	A1	19970522	WO 1996-US17882	19961108
	W: CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 876396	A1	19981111	EP 1996-942734	19961108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202175	A	19981216	CN 1996-198270	19961108
PRAI	US 1995-406330		19950317		
	US 1995-556597		19951113		
	WO 1996-US17882		19961108		

RE.CNT 29

RE
(1) Anon; WO 9109614 1991 CAPLUS
(2) Anon; WO 9209302 1992 CAPLUS
(3) Balass, M; Proc Natl Acad Sci USA 1993, V90, P10638 CAPLUS
(5) Christian, R; J Mol Biol 1992, V227, P711 CAPLUS
(6) Collen, D; Thrombosis and Haemostasis 1994, V71(1), P95 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1999:2009 CAPLUS
DN 130:206600
TI Investigation of S-farnesyl transferase substrate specificity with combinatorial tetrapeptide libraries
AU Boutin, Jean A.; Marande, William; Petit, Laurence; Loynel, Armelle; Desmet, Christine; Canet, Emmanuel; Fauchere, Jean-Luc
CS Department of Peptides, Institut de Recherches Servier, Suresnes, 92150, Fr.
SO Cell. Signalling (1998), Volume Date 1999, 11(1), 59-69
CODEN: CESIEY; ISSN: 0898-6568
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 52
RE
(1) Armstrong, S; J Biol Chem 1995, V270, P7864 CAPLUS
(2) Boutin, J; Anal Biochem 1996, V234, P126 CAPLUS
(3) Boutin, J; Arch Biochem Biophys 1998, V354, P83 CAPLUS
(4) Boutin, J; Cell Signal 1997, V9, P15 CAPLUS
(5) Boutin, J; Eur J Biochem 1993, V214, P853 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:683254 CAPLUS
DN 125:321431
TI A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture
AU Lin, Xueying; Tombler, Eugene; Nelson, Peter J.; Ross, Michael; Gelman, Irwin H.
CS Dep. Microbiol., Mount Sinai Sch. Med., New York, NY, 10029, USA
SO J. Biol. Chem. (1996), 271(45), 28430-28438
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596136 CAPLUS
DN 125:257215
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richard D.; Heath, William F.,Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9623513	A1	19960808	WO 1996-US946	19960129
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,				

NE, SN, TD, TG

US 5552524	A	19960903	US 1995-384292	19950206
AU 9647659	A1	19960821	AU 1996-47659	19960129
EP 810871	A1	19971210	EP 1996-903647	19960129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI US 1995-381661 19950131
US 1995-384292 19950206
US 1995-381037 19950131
US 1995-381049 19950131
US 1995-381054 19950131
US 1995-381163 19950131
US 1995-381666 19950131
US 1995-383632 19950206
US 1995-383649 19950206
US 1995-383650 19950206
US 1995-384492 19950206
WO 1996-US946 19960129

OS MARPAT 125:257215

L9 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596134 CAPLUS
DN 125:257213
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richard D.; Heath, William F., Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9623518	A1	19960808	WO 1996-US1345	19960129

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

US 5559208	A	19960924	US 1995-383639	19950206
AU 9648620	A1	19960821	AU 1996-48620	19960129
EP 809508	A1	19971203	EP 1996-904542	19960129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI US 1995-381031 19950131
US 1995-383639 19950206
WO 1996-US1345 19960129

OS MARPAT 125:257213

L9 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:596133 CAPLUS
DN 125:257212
TI Cloning and formulation of antiobesity proteins
IN Basinski, Margaret B.; Dimarchi, Richad D.; Heath, William F., Jr.; Schoner, Brigitte E.
PA Lilly, Eli, and Co., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9623519	A1	19960808	WO 1996-US1412	19960129

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,

ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE

	US 5552523	A	19960903	US 1995-384183	19950206
	AU 9647744	A1	19960821	AU 1996-47744	19960129
	EP 810872	A1	19971210	EP 1996-903766	19960129

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE

PRAI	US 1995-381458	19950131
	US 1995-384183	19950206
	WO 1996-US1412	19960129

OS MARPAT 125:257212

L9 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1996:435271 CAPLUS
DN 125:78553
TI High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
IN Knuth, Mark W.; Haak-Frendscho, Mary; Shultz, John W.; Lesley, Scott A.; Villars, Catherine E.
PA Promega Corporation, USA
SO PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9615249	A1	19960523	WO 1995-US14518	19951113

W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6069230	A	20000530	US 1994-338382	19941110
CA 2204914	AA	19960523	CA 1995-2204914	19951113
AU 9644623	A1	19960606	AU 1996-44623	19951113
AU 707030	B2	19990701		
EP 791068	A1	19970827	EP 1995-943330	19951113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 10509038	T2	19980908	JP 1995-516180	19951113
US 5989554	A	19991123	US 1998-174060	19981016

PRAI	US 1994-338382	19941110
	WO 1995-US14518	19951113

L9 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:880366 CAPLUS
DN 123:279695
TI C2 region-derived peptides inhibit translocation and function of .beta. protein kinase C in vivo
AU Ron, Dorit; Luo, Jianhua; Mochly-Rosen, Daria
CS Dep. Molecular Pharmacology, Stanford Univ., Stanford, CA, 94305-5332, USA
SO J. Biol. Chem. (1995), 270(41), 24180-7
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:842649 CAPLUS
DN 123:246823

TI Hydrophilic signal oligopeptides and methods of therapeutic use
IN Rath, Matthias
PA USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9519568	A1	19950720	WO 1995-US575	19950112
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9516810	A1	19950801	AU 1995-16810	19950112
	EP 744027	A1	19961127	EP 1995-908522	19950112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9881834	A1	19981008	AU 1998-81834	19980824
PRAI	US 1994-182248	19940114			
	WO 1995-US575	19950112			

L9 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1995:538212 CAPLUS
DN 122:291534
TI Preparation of peptide amides having smooth muscle relaxant activity as vasoactive intestinal polypeptide (VIP) analogs
IN Kishida, Tatsu; Konno, Fukio; Kawamoto, Takafumi; Kimura, Hitoshi; Osada, Naomi
PA Daicel Chem, Japan; Meiji Seika Co
SO Jpn. Kokai Tokkyo Koho, 29 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06092991	A2	19940405	JP 1991-34335	19910228
OS	MARPAT 122:291534				

L9 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1994:321360 CAPLUS
DN 120:321360
TI Immunoreactive peptides from Epstein-Barr virus (EBV)
IN Smith, Richard S.; Pearson, Gary R.; Parks, Elliot D.
PA Johnson and Johnson, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9406470	A1	19940331	WO 1993-US8699	19930915
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 671946	A1	19950920	EP 1993-921588	19930915
	EP 671946	B1	20000830		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08510714	T2	19961112	JP 1993-508271	19930915
	AU 693421	B2	19980702	AU 1993-49227	19930915

EP 889052 A2 19990107 EP 1998-113827 19930915
EP 889052 A3 19990818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
PRAI US 1992-945280 19920915
EP 1993-921588 19930915
WO 1993-US8699 19930915

L9 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1992:440432 CAPLUS
DN 117:40432
TI Novel immunosuppressant peptides
IN Gaeta, Federico C. A.; Powell, Michael F.; Grey, Howard M.; Sette, Alessandro D.; Arrhenius, Thomas S.
PA Cytel Corp., USA; Sandoz A.-G.; Sandoz-Patent-G.m.b.H.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9202543	A1	19920220	WO 1991-EP1420	19910729
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9183054	A1	19920302	AU 1991-83054	19910729
ZA 9106072	A	19930428	ZA 1991-6072	19910801
US 5679640	A	19971021	US 1995-400781	19950308

PRAI US 1990-560615 19900801
US 1991-654482 19910212
WO 1991-EP1420 19910729
US 1993-143973 19931027
OS MARPAT 117:40432

L9 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1992:99302 CAPLUS
DN 116:99302
TI Cell-cycle-dependent regulation of phosphorylation of human retinoblastoma gene product
IN Fung, Yuen Kai
PA Research Development Foundation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9109114	A1	19910627	WO 1990-US7216	19901207
W: AU, CA, DK, FI, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
ZA 9009755	A	19910925	ZA 1990-9755	19901205
IL 96575	A1	19950526	IL 1990-96575	19901206
CA 2070660	AA	19910608	CA 1990-2070660	19901207
CN 1052607	A	19910703	CN 1990-109950	19901207
AU 9170389	A1	19910718	AU 1991-70389	19901207
AU 653142	B2	19940922		
EP 504289	A1	19920923	EP 1991-901398	19901207
EP 504289	B1	19990915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 184653	E	19991015	AT 1991-901398	19901207
ES 2135390	T3	19991101	ES 1991-901398	19901207
NO 9202168	A	19920715	NO 1992-2168	19920601

FI 9202615 A 19920605 FI 1992-2615 19920605
PRAI US 1989-447282 19891207
WO 1990-US7216 19901207

L9 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2000 ACS
AN 1989:400067 CAPLUS
DN 111:67
TI Use of the membrane invasion culture system (MICS) as a screen for anti-invasive agents
AU Welch, Danny R.; Lobl, Thomas J.; Seftor, Elisabeth A.; Wack, Peter J.; Aeed, Paul A.; Yohem, Karin H.; Seftor, Richard E. B.; Hendrix, Mary J. C.
CS Dep. Cancer Infect. Dis. Res., Upjohn Co., Kalamazoo, MI, USA
SO Int. J. Cancer (1989), 43(3), 449-57
CODEN: IJCNAW; ISSN: 0020-7136
DT Journal
LA English